Tryp Therapeutics
Biotechnology, 8910 University Center Ln Ste 400, San Diego, California, 92122, United States, 1-10 Employees
Phone Number: 18*****
Who is TRYP THERAPEUTICS
Tryp Therapeutics is a clinical-stage biotechnology company focused on developing proprietary, novel formulations for the administration of psilocin in combination with psychotherapy to t...
Read More
-
Headquarters: 8910 University Center Ln Ste 400, San Diego, California, 92122, United States
-
Date Founded: 2019
-
Employees: 1-10
-
Revenue: $1 Million to $5 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 2834
|
NAICS Code: 325412 |
Show More
Does something look wrong? Fix it. | View contact records from TRYP THERAPEUTICS
Tryp Therapeutics Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Tryp Therapeutics
Answer: Tryp Therapeutics's headquarters are located at 8910 University Center Ln Ste 400, San Diego, California, 92122, United States
Answer: Tryp Therapeutics's phone number is 18*****
Answer: Tryp Therapeutics's official website is https://tryptherapeutics.com
Answer: Tryp Therapeutics's revenue is $1 Million to $5 Million
Answer: Tryp Therapeutics's SIC: 2834
Answer: Tryp Therapeutics's NAICS: 325412
Answer: Tryp Therapeutics has 1-10 employees
Answer: Tryp Therapeutics is in Biotechnology
Answer: Tryp Therapeutics contact info: Phone number: 18***** Website: https://tryptherapeutics.com
Answer: Tryp Therapeutics is a clinical-stage biotechnology company focused on developing proprietary, novel formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs. Tryps lead program, TRP-8803, is a proprietary formulation of IV-infused psilocin (the active metabolite of psilocybin) that alleviates numerous shortcomings of oral psilocybin including: significantly reducing the time to onset of the psychedelic state, controlling the depth and duration of the psychedelic experience, and reducing the overall duration of the intervention to a commercially feasible timeframe. The Company has an ongoing Phase 2a clinical trial for the treatment of Binge Eating Disorder at the University of Florida and an upcoming Phase 2a clinical trial with the University of Michigan for the treatment of fibromyalgia, both of which are utilizing TRP-8802 (synthetic, oral psilocybin) to demonstrate efficacy in these indications. Where a preliminary clinical benefit has been demonstrated, subsequent studies are expected to utilize TRP-8803 which has the potential to further improve efficacy, safety and patient experience.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month